A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Purpose
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Condition
- Migraine
Eligibility
- Eligible Ages
- Between 6 Years and 17 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria: - History of migraine attacks for more than 6 months - Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit - Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours - Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator - Participant must be able to swallow a tablet - For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening - Participants must weigh at least 15 kilograms (kg)
Exclusion Criteria
- Participants must not be pregnant or nursing - Participants must not have any acute, serious, or unstable medical condition - Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Lasmiditan High Dose |
Lasmiditan administered orally with matching placebo to maintain the blind. |
|
|
Experimental Lasmiditan Mid Dose |
Lasmiditan administered orally with matching placebo to maintain the blind. |
|
|
Experimental Lasmiditan Low Dose |
Lasmiditan administered orally with matching placebo to maintain the blind. |
|
|
Placebo Comparator Placebo |
Placebo administered orally. |
|
Recruiting Locations
Huntsville 4068590, Alabama 4829764 35805
256-885-9708
Scottsdale 5313457, Arizona 5551752 85254
480-471-6132
Tucson 5318313, Arizona 5551752 85718
520-320-2157
Los Angeles 5368361, California 5332921 90006
Ontario 5379439, California 5332921 91762
909-395-9788
New Haven 4839366, Connecticut 4831725 06510
Miami 4164138, Florida 4155751 33155
Miami 4164138, Florida 4155751 33165
305-226-3933
Miami Lakes 4164186, Florida 4155751 33015
305-793-1853
New Port Richey 4165869, Florida 4155751 34652
727-781-3655
Pensacola 4168228, Florida 4155751 32503
850-477-7900
Tampa 4174757, Florida 4155751 33612
Winter Park 4178560, Florida 4155751 32789
Union City 4227777, Georgia 4197000 30291
470-317-3604
Honolulu 5856195, Hawaii 5855797 96817
808-564-6141
Ammon 5583997, Idaho 5596512 83406
208-681-9070
Chicago 4887398, Illinois 4896861 60657
Naperville 4903279, Illinois 4896861 60563
Evansville 4257227, Indiana 4921868 47715
812-205-2475
Fort Wayne 4920423, Indiana 4921868 46804
260-436-2416x2179
Indianapolis 4259418, Indiana 4921868 46256
Newburgh 4262171, Indiana 4921868 47630
812-492-5011
West Des Moines 4881346, Iowa 4862182 50265
515-223-2300
Bowling Green 4285268, Kentucky 6254925 42101
270-685-4589
Lexington 4297983, Kentucky 6254925 40536
Owensboro 4303436, Kentucky 6254925 42301
270-685-4589
New Orleans 4335045, Louisiana 4331987 70118
New Orleans 4335045, Louisiana 4331987 70119
985-273-0855
East Lansing 4991640, Michigan 5001836 48824
517-884-8922
Burnsville 5019767, Minnesota 5037779 55337
Ridgeland 4443296, Mississippi 4436296 39157
601-617-7717
Monroe 4479946, North Carolina 4482348 28112
704-283-7359
Cincinnati 4508722, Ohio 5165418 45229
Cincinnati 4508722, Ohio 5165418 45236
513-898-9400
Portland 5746545, Oregon 5744337 97239
Scottdale 5211279, Pennsylvania 6254927 15683
724-220-5281
Smithfield 4561301, Pennsylvania 6254927 15478
724-569-8036
East Greenwich 5221875, Rhode Island 5224323 02818
Greenville 4580543, South Carolina 4597040 29607
864-334-0141
Waxahachie 4740328, Texas 4736286 75165
972-937-1640
Logan 5777544, Utah 5549030 84341
208-681-9070
Seattle 5809844, Washington 5815135 98105
206-987-2078
Huntington 4809537, West Virginia 4826850 25701
Kingwood 4811007, West Virginia 4826850 26537
304-441-2006
Caguas 4563008, Puerto Rico 00727
787-746-3136
Dorado 4564133, Puerto Rico 00646
7877961049
Ponce 4566880, Puerto Rico 00716
787-840-2505
Vega Baja 4568533, Puerto Rico 694
787-654-9444
More Details
- NCT ID
- NCT04396236
- Status
- Recruiting
- Sponsor
- Eli Lilly and Company
Study Contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
LillyTrials@Lilly.com